Novo Nordisk trims price for blockbuster obesity drug as competition heats up
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Novo Nordisk trims price for blockbuster obesity drug as competition heats up
May 6, 2024 9:30 AM EDT
Citi analysts said in a note Monday that they believe history shows the dip in one major pharmaceutical company's shares should be bought.
The investment bank said Novo Nordisk (NYSE: NVO) remains Buy-rated, while the firm also maintained a Dkr975.00 price target on the stock.... More
May 3, 2024 5:55 AM EDT
BofA Securities analyst Sachin Jain reiterated a Buy rating and $147.00 price target on Novo Nordisk (NYSE: NVO)
The analyst comments "Key takes from 1Q results: 1) 1Q24 adjusted EPS DKK5.68 +29%, 8% ahead of consensus, on 2% sales beat and operating margin 300bps ahead, mainly on S&D, offset by lower OOI (-DKK568m vs +DKK33m,... More
May 2, 2024 6:23 AM EDT
Novo Nordisk (NYSE: NVO) reported a robust first quarter with a 24% increase in sales at constant exchange rates (CER), reaching DKK 65.35 billion. The company's operating profit also saw a significant rise, jumping by 30% at CER to DKK 31.8 billion. Despite these strong results, shares of the pharmaceutical giant fell by 2.83%.
The first quarter's performance was marked by a notable 34% sales increase in North America Operations, with a 35% increase at CER. This growth was largely attributed to adjustments in gross-to-net sales from previous years. International Operations also saw an 11% rise at CER. Within the... More
